SEC Form 4 · accession 0001493152-17-004210
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel S. Hoverman
Director
Period of report
Apr 17, 2017
Accepted (ET)
Apr 20, 2017 · 8:49 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.27 | Apr 17, 2017 | A | 350,000 | A | Apr 17, 2018 | Apr 17, 2027 | Common Stock | 350,000 | 350,000 | D |
Explanation of responses
- F1Shares issued as compensation approved by the Issuer's Board of Directors.